Evaluation of MP4OX for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: a randomized, double-blind, multicenter study
- PMID: 21455059
- DOI: 10.1097/ALN.0b013e318215e198
Evaluation of MP4OX for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: a randomized, double-blind, multicenter study
Abstract
Background: MP4OX (oxygenated polyethylene glycol-modified hemoglobin) is an oxygen therapeutic agent with potential applications in clinical settings where targeted delivery of oxygen to ischemic tissues is required. The primary goal of this study was to investigate MP4OX for preventing hypotensive episodes. An additional goal was to establish the safety profile of MP4OX in a large surgical population.
Methods: Patients (n = 367) from 18 active study sites in six countries, undergoing elective primary hip arthroplasty with spinal anesthesia, were randomized to receive MP4OX or hydroxyethyl starch 130/0.4. Patients received a 250-ml dose at induction of spinal anesthesia and a second 250-ml dose if the protocol-specified trigger (predefined decrease in systolic blood pressure) was reached. The primary end point was the proportion of patients who developed one or more hypotensive episodes.
Results: The proportion of patients with one or more hypotensive episodes was significantly lower (P < 0.0001) in the MP4OX group (66.1%) versus controls receiving hydroxyethyl starch 130/0.4 (90.2%). More MP4OX-treated patients experienced adverse events compared with controls (72.7% vs. 61.4%; P = 0.026). Transient elevations in laboratory values (e.g., alanine aminotransferase, aspartate aminotransferase, lipase, and troponin concentrations) occurred more frequently in the MP4OX group. There were no significant differences in the incidence of serious adverse events or in the composite morbidity and ischemia outcome end points, but nausea and hypertension were reported more often in MP4OX-treated patients.
Conclusion: MP4OX significantly reduced the incidence of hypotensive episodes in patients undergoing hip arthroplasty, but the adverse event profile does not support use in routine low-risk surgical patients for the indication evaluated in this study.
Comment in
-
Hemoglobin-based oxygen carriers for reversing hypotension and shock: "NO" way, "NO" how?Anesthesiology. 2011 May;114(5):1016-8. doi: 10.1097/ALN.0b013e318215e20b. Anesthesiology. 2011. PMID: 21521965 No abstract available.
Similar articles
-
A double-blind, randomized, multicenter study of MP4OX for treatment of perioperative hypotension in patients undergoing primary hip arthroplasty under spinal anesthesia.Anesth Analg. 2011 Apr;112(4):759-73. doi: 10.1213/ANE.0b013e31820c7b5f. Epub 2011 Feb 11. Anesth Analg. 2011. PMID: 21317165 Clinical Trial.
-
A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery.Anesthesiology. 2006 Dec;105(6):1153-63. doi: 10.1097/00000542-200612000-00015. Anesthesiology. 2006. PMID: 17122578 Clinical Trial.
-
A randomized trial comparing colloid preload to coload during spinal anesthesia for elective cesarean delivery.Anesth Analg. 2009 Oct;109(4):1219-24. doi: 10.1213/ane.0b013e3181b2bd6b. Epub 2009 Jul 29. Anesth Analg. 2009. PMID: 19641050 Clinical Trial.
-
Hetastarch co-loading is as effective as pre-loading for the prevention of hypotension following spinal anesthesia for cesarean delivery.Int J Obstet Anesth. 2009 Apr;18(2):150-5. doi: 10.1016/j.ijoa.2008.12.006. Epub 2009 Feb 14. Int J Obstet Anesth. 2009. PMID: 19223168 Clinical Trial.
-
[Hemoglobin solutions: volume replacement or oxygen therapy?].Anasthesiol Intensivmed Notfallmed Schmerzther. 1998 Nov;33(11):699-714. doi: 10.1055/s-2007-994841. Anasthesiol Intensivmed Notfallmed Schmerzther. 1998. PMID: 9861432 Review. German.
Cited by
-
Hemoglobin-Based Blood Substitutes and the Treatment of Sickle Cell Disease: More Harm than Help?Biomolecules. 2017 Jan 4;7(1):2. doi: 10.3390/biom7010002. Biomolecules. 2017. PMID: 28054978 Free PMC article. Review.
-
Therapeutic Potential of Hemoglobin Derived from the Marine Worm Arenicola marina (M101): A Literature Review of a Breakthrough Innovation.Mar Drugs. 2021 Jun 29;19(7):376. doi: 10.3390/md19070376. Mar Drugs. 2021. PMID: 34210070 Free PMC article. Review.
-
Mechanisms of Toxicity and Modulation of Hemoglobin-based Oxygen Carriers.Shock. 2019 Oct;52(1S Suppl 1):41-49. doi: 10.1097/SHK.0000000000001044. Shock. 2019. PMID: 29112106 Free PMC article. Review.
-
PEGylated Bovine Carboxyhemoglobin (SANGUINATE™): Results of Clinical Safety Testing and Use in Patients.Adv Exp Med Biol. 2016;876:461-467. doi: 10.1007/978-1-4939-3023-4_58. Adv Exp Med Biol. 2016. PMID: 26782246
-
Hemoglobin-based oxygen carriers, oxidative stress and myocardial infarction.Front Physiol. 2025 Apr 15;16:1551932. doi: 10.3389/fphys.2025.1551932. eCollection 2025. Front Physiol. 2025. PMID: 40303592 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical